Company Overview
Amphastar Pharmaceuticals, Inc. functions as a bio-pharmaceutical entity dedicated to the development, manufacturing, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products across the United States, China, and France. The company operates within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, positioning it to serve specialized therapeutic needs that require distinct production capabilities beyond standard pharmaceutical manufacturing. The firm currently maintains a market capitalization of $883.66M, generates annual revenue of $719.89M, and employs a workforce of 1976 individuals to support its operational footprint. These financial dimensions indicate a mid-cap enterprise with a substantial revenue base that supports a significant employee count, suggesting established market presence and operational scale within its niche of specialty and generic drug production.
Financial Health
The company reported revenue of $719.89M and net income of $98.09M over the trailing twelve months, resulting in an EBITDA of $220.20M. The substantial gap between the $719.89M revenue and the $98.09M net income reveals a cost structure where expenses, including cost of goods sold and operating expenditures, consume approximately 86.4% of total revenue before reaching the bottom line. Amphastar generated free cash flow of $81.37M, which indicates a positive cash generation capability that provides the organization with financial flexibility to fund operations, service debt obligations, or pursue strategic initiatives without immediate reliance on external financing. The company maintains a gross margin of 49.5%, an operating margin of 19.4%, and a profit margin of 13.6%, where the high gross margin reflects efficient production costs relative to sales, the operating margin demonstrates effective control over administrative and selling expenses, and the profit margin shows the final efficiency of converting revenue into retained earnings. Regarding liquidity and leverage, the firm holds $282.81M in cash against $656.00M in total debt, resulting in a debt-to-equity ratio of 83.16, which suggests a balance sheet that is leveraged with debt significantly exceeding cash reserves. Despite the debt load, the current ratio stands at 4.02, indicating a strong short-term liquidity position where current assets are more than four times current liabilities, ensuring the ability to meet short-term obligations comfortably. Return on Equity is reported at 12.9% and Return on Assets at 6.4%, metrics that reveal management's effectiveness in generating profits from shareholder equity and utilizing total assets to produce earnings respectively.
Valuation Assessment
Amphastar Pharmaceuticals trades with a P/E Ratio of 9.47 on a trailing twelve-month basis and a forward P/E of 5.51, where the significant difference between these two metrics implies that the market expects earnings to decline substantially in the coming year compared to historical performance. The price-to-book ratio is 1.11, indicating that the stock trades at a slight premium over its book value, suggesting investors value the company's intangible assets and brand equity slightly higher than the accounting book value of its net assets. Alternative valuation metrics include a price-to-sales ratio of 1.23 and an EV/EBITDA of 5.66, which suggest the market values the company based on a multiple of its sales and earnings power that is consistent with the current economic cycle for specialty generic manufacturers. In terms of trading range, the stock has a 52-week high of $31.26 and a 52-week low of $17.03, meaning the current price sits within this historical range and reflects recent price volatility relative to its yearly peaks and troughs. The stock exhibits a beta of 0.92, which signifies that its price volatility is slightly lower than the broader market, moving in tandem with general market trends but with slightly less sensitivity to market-wide fluctuations.
Growth & Income
The company experienced a revenue growth rate of -1.8% and an earnings growth rate of -31.0% year over year, indicating that earnings are shrinking at a much faster pace than revenue, which implies potential headwinds in pricing, volume, or cost efficiencies that are disproportionately affecting the bottom line. Amphastar does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests its earnings into growth initiatives, debt reduction, or share repurchases rather than distributing cash to shareholders. The overall growth and income profile is characterized by negative earnings growth and a lack of dividend distribution, presenting a capital appreciation play rather than an income-generating investment within the specialty pharmaceutical space. The firm's financial structure relies on retained earnings and operational cash flow to sustain its operations while navigating the current contraction in reported earnings.